238 related articles for article (PubMed ID: 620410)
21. Cross-linking of DNA in L1210 cells and nuclei treated with cyclophosphamide and phosphoramide mustard.
Surya YA; Rosenfeld JM; Hillcoat BL
Cancer Treat Rep; 1978 Jan; 62(1):23-9. PubMed ID: 564237
[TBL] [Abstract][Full Text] [Related]
22. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Voelcker G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
[TBL] [Abstract][Full Text] [Related]
23. Identification of phosphorodiamidic acid mustard as a human metabolite of cyclop hosphamide.
Fenselau C; Kan MN; Billets S; Colvin M
Cancer Res; 1975 Jun; 35(6):1453-7. PubMed ID: 1131817
[TBL] [Abstract][Full Text] [Related]
24. Kinetics of hydrolysis in vitro of nornitrogen mustard, a metabolite of phosphoramide mustard and cyclophosphamide.
Hemminki K; Alhonen A; Linkola E; Hesso A
Arch Toxicol; 1987 Dec; 61(2):126-30. PubMed ID: 3439884
[TBL] [Abstract][Full Text] [Related]
25. Covalent sequestration of phosphoramide mustard by metallothionein--an in vitro study.
Wei D; Fabris D; Fenselau C
Drug Metab Dispos; 1999 Jul; 27(7):786-91. PubMed ID: 10383921
[TBL] [Abstract][Full Text] [Related]
26. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
28. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.
Struck RF; Alberts DS; Horne K; Phillips JG; Peng YM; Roe DJ
Cancer Res; 1987 May; 47(10):2723-6. PubMed ID: 3552204
[TBL] [Abstract][Full Text] [Related]
29. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry.
Yuan ZM; Smith PB; Brundrett RB; Colvin M; Fenselau C
Drug Metab Dispos; 1991; 19(3):625-9. PubMed ID: 1680629
[TBL] [Abstract][Full Text] [Related]
30. Relative mutagenicity of some urinary metabolites of the antitumor drug cyclophosphamide.
Balbinder E; Reich CI; Shugarts D; Keogh J; Fibiger R; Jones T; Banks A
Cancer Res; 1981 Jul; 41(7):2967-72. PubMed ID: 7018675
[TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.
Juma FD; Rogers HJ; Trounce JR
Br J Clin Pharmacol; 1980 Oct; 10(4):327-35. PubMed ID: 7448105
[No Abstract] [Full Text] [Related]
32. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide.
Gilbert DN; Starr P; Eubanks N
Cancer Res; 1977 Feb; 37(2):456-9. PubMed ID: 832269
[TBL] [Abstract][Full Text] [Related]
33. Identification of new metabolites of phosphoramide and nor-nitrogen mustards and cyclophosphamide in rat urine using ion cluster techniques.
Chan KK; Hong SC; Watson E; Deng SK
Biomed Environ Mass Spectrom; 1986 Mar; 13(3):145-54. PubMed ID: 2938656
[TBL] [Abstract][Full Text] [Related]
34. Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry.
Przybylski M
Arzneimittelforschung; 1982; 32(9):995-1012. PubMed ID: 6756419
[TBL] [Abstract][Full Text] [Related]
35. Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry.
Kalhorn TF; Howald WN; Cole S; Phillips B; Wang J; Slattery JT; McCune JS
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 835(1-2):105-13. PubMed ID: 16581318
[TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
Friedman OM; Wodinsky I; Myles A
Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
[TBL] [Abstract][Full Text] [Related]
37. Cyclophosphamide metabolism in children.
Yule SM; Boddy AV; Cole M; Price L; Wyllie R; Tasso MJ; Pearson AD; Idle JR
Cancer Res; 1995 Feb; 55(4):803-9. PubMed ID: 7850793
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
39. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro.
Hales BF
Teratology; 1989 Jul; 40(1):11-20. PubMed ID: 2763206
[TBL] [Abstract][Full Text] [Related]
40. N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard.
Jiang Y; Hu L
Bioorg Med Chem Lett; 2008 Jul; 18(14):4059-63. PubMed ID: 18556201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
